BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/27/2026 8:35:10 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-10-25 09:01 |
|
Peer-Review Started |
|
2025-10-25 09:01 |
|
First Decision by Editorial Office Director |
|
2025-11-24 12:55 |
|
Return for Revision |
|
2025-11-24 12:55 |
|
Revised |
|
2025-12-02 22:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-04 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-04 07:25 |
|
Articles in Press |
|
2026-01-04 07:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-10 08:14 |
|
Publish the Manuscript Online |
|
2026-02-27 08:35 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yasser Fouad and Ahmed S Aboelela |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine, Minia University, El Horryia Street, Minia 19111, Egypt. yasserfouad10@yahoo.com |
| Key Words |
Tofacitinib; Ulcerative colitis; Induction therapy; Maintenance therapy; Janus kinase |
| Core Tip |
Partial or delayed responders with ulcerative colitis can be saved by extending tofacitinib induction from 8 weeks to 16 weeks without raising safety concerns. Evidence from the real world shows that this approach, especially in patients with biologic experience, results in higher remission rates and long-lasting drug persistence. Instead of a strict 8-week limit, a structured, response-guided algorithm enables clinicians to address modifiable risk factors like smoking, maximize long-term outcomes, and customize therapy. Now, extended induction ought to be seen as a logical, scientifically supported part of customized tofacitinib treatment. |
| Publish Date |
2026-02-27 08:35 |
| Citation |
Fouad Y, Aboelela AS. Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis. World J Gastroenterol 2026; 32(9): 115785 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i9/115785.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i9.115785 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
